Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: Results from beta-confident registry

Pediatric Rheumatology

Volumn 13, Issue 1, 2015, Pages

  Kuemmerle Deschner, J ^a   Hoffman, H ^b   Hawkins, P N ^c   van der Poll, T ^d   Walker, U A ^e   Speziale, A ^f   Tilson, H H ^g  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f NOVARTIS PHARMA AG   (Switzerland)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAKINUMAB;

ARTICLE; CINCA SYNDROME; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; INFECTION; INFESTATION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME; VERTIGO;

EID: 84956729351     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/1546-0096-13-S1-P3     Document Type: Article

References (1)

1. Kuemmerle-Deschner JB, et al: Arthritis Res Ther. 2011, 13 (1): R34-10.1186/ar3266.